Histopathology · 2015 · 20 citations · 29 references
MedicineDermatologyOncologyMolecular OncologyNeoplasiaTumor MicroenvironmentCancer Molecular PathologyMalignant NeoplasmsMelanocytic LesionsMelanocytic TumorsRedox SignalingSkin TumorsEnzymesMalignant Melanocytic TumorsMelanocytic Tumor ImmunohistochemistryMelanocytic Tumor PrognosisOxidative Stress In CancerPeroxiredoxin Expression PatternsRadiation-induced Oxidative StressUltraviolet Radiation Stress
AIMS: To investigate redox-regulating enzymes that may have a special role in melanoma pathogenesis due to continuous exposure to microenvironment-produced and ultraviolet radiation-induced oxidative stress. METHODS AND RESULTS: We assessed immunohistochemically the expression of antioxidant enzymes peroxiredoxins (Prxs) I-IV, sulfiredoxin (Srx) and redox-regulated proto-oncogene DJ-1 in material consisting of 30 benign naevi, 14 lentigo malignas and 67 malignant melanomas. Evaluation of immunostaining was performed with special attention paid to protein expression in different tumour compartments. In particular, the expression patterns of nuclear Prx I and Prx II and cytoplasmic DJ-1 were decreased significantly in melanomas compared with dysplastic and benign naevi. In multivariate analysis, several prognostic factors were identified: Prx III expression in the cytoplasm of stromal fibroblasts was associated with shortened melanoma-specific survival [hazard ratio (HR) 6.730; 95% confidence interval (CI) 1.579-28.689], while cytoplasmic Prx IV expression in endothelial cells (HR 6.563; 95% CI 1.750-24.620) and Srx expression in the cytoplasm of keratinocytes (HR 6.988; 95% CI 1.559-31.324) were associated with better prognosis independently of ulceration, thickness of melanoma or its diagnostic type. CONCLUSIONS: Redox-regulating enzymes have the potential to serve as novel prognostic factors and targeting them may offer new therapeutic options in malignant melanoma.
29
Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma
Vuokko L. Kinnula, Siri Lehtonen, Raija Sormunen et al. · The Journal of Pathology · 2002 · 233 citations
Peroxiredoxins in breast carcinoma.
Peeter Karihtala, Anne Mäntyniemi, Sang Won Kang et al. · PubMed · 2003 · 233 citations
Peroxiredoxins, a novel protein family in lung cancer
Siri Lehtonen, Anne‐Mari Svensk, Ylermi Soini et al. · International Journal of Cancer · 2004 · 174 citations · Full text